Market GrowthThe ATTR-CM market is projected to grow to approximately $20B, with unrealized value seen for Attruby, indicating significant growth potential.
Product LaunchThe Attruby launch in ATTR-CM is off to a strong start and is expected to exceed expectations, becoming the preferred 1st-line option due to ease of procurement and administration.
Regulatory ApprovalThe FDA has indicated willingness to grant accelerated approval based on the surrogate biomarker endpoint of αDG glycosylation increase.
Strategic CapitalRoyalty monetization provides minimally dilutive capital, increasing strategic flexibility.